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Background: We determined the protective effects of a high dose of ulinastatin on myocardial and renal function in 
patients undergoing aortic valve replacement with cardiopulmonary bypass (CPB). 
Methods: Sixty patients were assigned randomly to either the ulinastatin group (n = 30) or the control group (n = 30). 
In the ulinastatin group, ulinastatin (300,000 U) was given after the induction of anesthesia, ulinastatin (400,000 U) 
was added to the CPB pump prime, and then ulinastatin (300,000 U) was administered after weaning from CPB. In 
the control group, the same volume of saline was administered at the same time points. Creatine kinase-MB levels 
were assessed 1 day before surgery, and on the first and second postoperative day (POD 1 and 2). Serum creatinine 
and cystatin C levels were assessed 1 day before surgery, upon intensive care unit arrival, and on POD 1 and 2. The 
level of plasma neutrophil gelatinase-associated lipocalin was assessed before induction of anesthesia, upon ICU 
arrival, and on POD 1. 
Results: No significant differences were observed in serum levels of creatine kinase-MB and biomarkers of renal 
injury between the two groups at any point during the study period. 
Conclusions: Ulinastatin showed no cardiac or renal protective effects after CPB in patients undergoing aortic valve 
replacement. (Korean J Anesthesiol 2012; 62: 148-153)
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Introduction
Open heart surgery using cardiopulmonary bypass (CPB) is 
invariably accompanied by a systemic inflammatory response 
and multiple-organ ischemia/reperfusion (I/R) injury [1]. 
Myocardial dysfunction and acute renal injury after CPB, which 
lead to a prolonged postoperative hospital stay, continue to 
be the subject of a considerable amount of clinical research. 
Although the mechanisms of CPB-associated myocardial 
and renal injury have yet to be fully elucidated, the release of 
protease enzymes, cytokines, and oxygen free radicals from 
activated neutrophils results in endothelial injury, platelet 
activation, and a sequential inflammatory cascade, leading to 
post-pump organ injury [2-6].
Ulinastatin, a urinary trypsin inhibitor, is a nonspecific pro-
tease inhibitor and glycoprotein that is extracted and purified 
from human urine. It suppresses inflammatory activity, infil-
tration of neutrophils, and release of elastase and chemical 
mediators from neutrophils [7-12]. In addition, ulinastatin 
protects mitochondrial function by directly inhibiting lysosomal 
enzymes and oxygen free radicals in cells and by reducing 
calcium overload in injured cells [13]. Ulinastatin may reduce 
post-pump myocardial and renal injury by suppressing the 
release of proinflammatory cytokines and neutrophil elastase. 
Although some studies have reported that ulinastatin has a 
beneficial effect on I/R injury of the heart and kidneys, the 
sample sizes of these studies were too small to determine 
clinical outcome after open heart surgery under CPB [12,14]. 
Additionally, little is known about whether a high dose of 
ulinastatin (1,000,000 U) protects the heart and kidneys from I/
R injury in adult patients undergoing valvular heart surgery. 
Therefore, we performed a prospective, randomized, double-
blind, placebo-controlled clinical study with a homogeneous 
group of patients undergoing aortic valve replacement. Our 
aim was to evaluate whether the administration of high dose 
ulinastatin could provide myocardial and renal protection 
during CPB.
Materials and Methods
After approval of this study protocol by our Institutional 
Review Board, we obtained informed consent from 60 adult 
patients scheduled for elective aortic valve replacement 
between February 2009 and March 2011. We excluded patients 
who underwent combined valve and coronary-artery bypass 
grafting procedures, those with active infective endocarditis, 
hepatic or pulmonary disease, left ventricular ejection fraction 
< 30%, pre-existing renal dysfunction (serum creatinine level 
> 1.6 mg/dl for men and 1.4 mg/dl for women), those older 
than 80 years, and those who had undergone reoperations. 
All preoperative cardiac medications, except diuretics, 
were continued until the day of surgery. All patients received 
standardized anesthetic management. Standard monitoring 
devices were used in the operating room. Anesthesia was 
induced with intravenous midazolam (0.03-0.07 mg/kg), 
sufentanil (1.5-3.0 μg/kg), and 0.9 mg/kg rocuronium bromide, 
and maintained with sevoflurane (0.8-1.5%) and continuous 
infusion of sufentanil (0.5-1.5 μg/kg/hr). After intubation, 
the patient’s lungs were ventilated with a tidal volume of 8 ml/
kg, an inspiratory/expiratory time ratio of 1 : 2, and a positive 
end-expiratory pressure of 5 cm H2O in 40% oxygen with air. 
Respiratory rate was adjusted to between 8 and 12 breaths/min 
to maintain normocarbia.
After induction of anesthesia, patients were assigned ran-
domly to either the ulinastatin group (n = 30) or the control 
group (n = 30), using a computerized randomization table. 
An anesthesia research nurse prepared the syringes of 
blinded solution that were administered by the attending 
anesthesiologist. In the ulinastatin group, patients received 
300,000 U ulinastatin intravenously in 50 ml normal saline for 
15 min after the induction of anesthesia with 400,000 U added 
to the CPB pump prime, followed by an intravenous infusion 
of 300,000 U ulinastatin in 50 ml normal saline for 15 min after 
weaning from CPB. Patients received similar volumes of normal 
saline in the control group. All physicians caring for patients 
were blinded to the treatment allocation. 
All patients received standardized surgical and CPB manage-
ment. CPB was instituted with a membrane oxygenator primed 
with 1,200 ml of crystalloid solution, 200 ml of 20% mannitol, and 
100 ml of 20% albumin. Surgical procedures were performed 
under mild hypothermia (32-33
oC). Acid-base management 
was performed with the α-stat method, and the target range for 
PaO2 was 200-300 mmHg. The non-pulsatile pump flow rate 
was maintained at 2.0-2.5 L/min/m
2, and a blood cardioplegic 
solution was used. Patients were weaned from CPB after 
completion of the surgical procedure and systemic re-warming. 
During the perioperative period and CPB, mean arterial 
pressure was maintained at 60-80 mmHg. Norepinephrine 
was used for vasopressor support and milrinone for inotropic 
support. The threshold for transfusion of packed red blood cells 
was a hematocrit < 20% during CPB and 25% after CPB. The 
blood from the CPB circuit was salvaged (cell salvage device) 
after heparin was reversed and retransfused after sternal 
closure. Urine output and all fluids administered to patients 
were recorded until the first postoperative day (POD1). 
All patients were transferred to the intensive care unit (ICU) 
after surgery, where they received management according 
to institutional guidelines. Fluid therapy was administered 
postoperatively to maintain pulmonary capillary wedge 
pressure at 10-14 mmHg, cardiac index > 2 L/min/m
2, and 150 www.ekja.org
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urine output > 0.5 ml/kg/h. The duration of ventilation, length 
of ICU stay, and postoperative hospitalization length of stay 
were recorded. 
Hemodynamic variables, including the cardiac index 
and the number of patients requiring norepinephrine, were 
recorded 15 min after tracheal intubation, 15 min after sternal 
closure, and 1 and 24 hours after ICU arrival. Serum creatinine 
and cystatin C levels were assessed 1 day before surgery, upon 
ICU arrival, and on POD 1 and the second postoperative day 
(POD 2). Blood samples were collected to measure levels of 
plasma neutrophil gelatinase-associated lipocalin (NGAL) 
before induction of anesthesia, upon ICU arrival, and on POD 1. 
Serum was separated from blood by centrifugation and stored 
at -70
oC until assay. Plasma NGAL levels were measured 
using a commercially available ELISA kit (Human Lipocalin-2/
NGAL Immunoassay R&D Systems, Minneapolis, MN, USA), 
according to the manufacturer’s instructions. Creatine kinase-
MB (CK-MB) levels were assessed 1 day before surgery and on 
POD 1 and 2. 
The primary endpoint was to compare post-pump myocardial 
enzyme leakage between the ulinastatin and control groups 
using the levels of serum CK-MB and serum biomarkers of renal 
injury, including serum creatinine, cystatin C, and NGAL. 
Based on data from a previous study, the mean and standard 
deviation of postoperative CK-MB level, which is an index of 
myocardial injury, is 40 ± 15 μg/L in patients undergoing aortic 
valve replacement [15]. We accepted that a 30% reduction in 
CK-MB level represented a clinically significant benefit. We 
estimated that a sample of 26 patients per group would be 
sufficient to detect a mean difference between groups with a 
power of 0.8 and a type I error of 0.05. Factoring in a drop-out 
rate of ~10%, we calculated that 30 patients would be required 
for each group. 
Data were analyzed with SPSS 18.0 (SPSS Inc., Chicago, 
IL, USA) and expressed as mean ± SD or number of patients. 
Data between the groups were compared using the chi-square 
test, Fisher’s exact test, independent t-test, or Mann-Whitney 
U-test, as appropriate. Repeated-measures analysis of variance 
followed by a post-hoc Dunnett’s test was used for intragroup 
comparisons of variables compared to baseline values. A 
P value < 0.05 was considered statistically significant.
Results
Patients in the two groups had similar characteristics. The 
mean duration of CPB and aortic cross-clamp were not different 
between the groups (Table 1). No significant differences in 
serum levels of CK-MB, creatinine, cystatin C, or NGAL were 
observed between the groups throughout the study period 
(Table 2). 
The total volume of fluid infused and urine output were 
similar between the two groups during the operation and the 
first 24 hr in the ICU. The total amount of pRBCs transfused 
between the groups was similar during the operation and for 
the first 48 hr in the ICU (Table 3). 
Table 1. Patient Characteristics and Operative Data
Variable
Control  
group
(n = 30)
Ulinastatin 
group
(n = 30)
P value
Age (yr)
Gender (M/F)
Body surface area (m
2)
Diabetes 
Hypertension 
Atrial fibrillation
LVEF (%)
Pre-operative medications
    ACE-I/ARB
    Calcium channel blocker 
    β-blockers
    Diuretics
NYHA class III or IV
Duration of ACC (min)
Duration of CPB (min)
60 ± 12
16/14
1.6 ± 0.2
3 (10)
7 (23)
0
62 ± 14
12 (40)
5 (17)
4 (13)
15 (50)
4 (13)
76 ± 21
96 ± 22
67 ± 19
20/10
1.7 ± 0.2
3 (10)
13 (43)
1 (3)
63 ± 11
6 (20)
7 (23)
3 (10)
8 (27)
4 (13)
74 ± 19
99 ± 25
 0.09
 0.43
 0.12
 1.00
 0.10
 0.49
 0.97
 0.16
 0.53
 1.00
 0.11
 1.00
 0.73
 0.64
Values are mean ± SD or number of patients (%). LVEF: left ventri-
cular ejection fraction, ACE-I: angiotensin converting enzyme inhi-
bitor, ARB: angiotensin receptor blocker, NYHA: New York Heart 
Association, ACC: aorta cross clamp, CPB: cardiopulmonary bypass.
Table 2. Changes in Preoperative and Postoperative Cardiac and Renal Biomarkers
Variables Group Baseline ICU arrival POD 1 POD 2
CK-MB (ng/ml)
Creatinine (mg/dl)
Cystatin C (mg/L)
Plasma NGAL  (ng/ml)
    
Control
Ulinastatin
Control
Ulinastatin
Control
Ulinastatin
Control
Ulinastatin
4.2 ± 1.8
2.7 ± 0.9
1.0 ± 0.2
1.0 ± 0.2
1.0 ± 0.2
0.9 ± 0.2
41 ± 21
57 ± 51
0.9 ± 0.2
0.9 ± 0.1
0.8 ± 0.2
0.8 ± 0.2
149 ± 58
151 ± 57
26.1 ± 13.9
22.5 ± 9.2
1.0 ± 0.3
1.1 ± 0.2
0.9 ± 0.3
0.9 ± 0.3
144 ± 51
148 ± 57
18.5 ± 9.7
16.4 ± 7.1
1.0 ± 0.2
1.0 ± 0.2
1.0 ± 0.3
1.2 ± 0.3
Values are mean ± SD or number of patients. ICU: intensive care unit, POD: postoperative day, CK-MB: creatine kinase-MB, NGAL: neutrophil 
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Hemodynamic variables, including the cardiac index, were 
not significantly different between the groups throughout the 
study period (Table 4). The total amount of norepinephrine 
used during weaning from CPB did not differ between the 
control group and the ulinastatin group (200 ± 158 μg vs. 230 ± 
158 μg, P = 0.471). 
The time to extubation, postoperative length of stay in the 
ICU, and postoperative hospitalization period were also similar 
between the two groups (Table 5). 
Discussion
In this prospective, randomized trial designed to investigate 
the myocardial and renal protective effects of a high dose of 
ulinastatin in patients undergoing aortic valve replacement, we 
did not observe any beneficial effects of ulinastatin, as assessed 
by monitoring serum biomarkers of myocardial and renal 
injury. 
Ulinastatin is a complex polypeptide extracted from human 
urine that suppresses the release of inflammatory chemical 
mediators such as polymorphonuclear neutrophil elastase 
(PMNE), tumor necrosis factor-alpha, interleukin (IL)-6, and IL-
8. Several studies have suggested that ulinastatin can reduce I/R 
injuries of major organs such as the kidneys, lungs, and liver [4,9-
12,16]. While ulinastatin was revealed to have a protective effect 
on myocardial injury in animal experiments (15,000 U/kg) and 
pediatric patients (12,000 U/kg) [14,17], adult cardiac surgery 
studies (5,000-6,000 U/kg) have reported conflicting results 
[18,19]. In these studies, doses of ulinastatin administered to 
adult patients were relatively small compared to those used 
in animal experiments and in pediatric studies [14,17-19]. 
However, patients who underwent coronary-artery bypass 
graft surgery (CABG) with CPB and who received 1,000,000 
U ulinastatin have lower levels of PMNE and inflammatory 
cytokines than those in a control group, and their weaning 
time from mechanical ventilation is shortened [4]. Therefore, 
we performed this clinical study to evaluate the impact of a 
high dose of ulinastatin (1,000,000 U) on myocardial and renal 
injury in a homogeneous group of patients. However, we did 
not observe myocardial and renal protection effects in adult 
Table 3. Perioperative Fluid Balance and Transfusion Data
Variable
Control  
group 
(n = 30)
Ulinastatin 
group 
 (n = 30)
P value
Fluid input (ml)
    OR
    ICU 24 hr
Urine output (ml) 
    OR
    ICU 24 hr
Blood loss during ICU 24 hr (ml)
pRBC transfused (units)
    OR
    ICU 24 hr
    ICU 24-48 hr
1,958 ± 545
4,599 ± 667
1,239 ± 1,713
3,299 ± 651
338 ± 198
0.8 ± 0.9
0.2 ± 0.6
0.1 ± 0.5
2,200 ± 676
4,342 ± 886
986 ± 427
3,231 ± 852
394 ± 220
0.6 ± 0.8
0.6 ± 0.9
0.2 ± 0.6
0.23
0.14
0.42
0.47
0.57
0.55
0.17
0.74
Values are mean ± SD. OR: operating room, ICU: intensive care unit, 
pRBC: packed red blood cells.
Table 5. Postoperative Outcome Data
Variable
Control 
group 
(n = 30)
Ulinastatin 
group 
 (n = 30)
P 
value
Reintubation
Time on ventilator (hr)
Norepinephrine use  
ICU stay (days) 
Postoperative hospital stay (days)
0
16.1 ± 4.5
6 (20)
2.9 ± 0.7
9.4 ± 4.9
1
16.7 ± 4.8
9 (30)
3.0 ± 0.4
10.4 ± 6.2
1.00
0.66
0.70
0.98
0.55
Values are mean ± SD or number of patients (%). ICU: intensive care 
unit. 
Table 4. Changes in Hemodynamic Variables at Various Time Points
Variables Group T1 T2 T3 T4
HR (beats/min)
MAP (mmHg)
MPAP (mmHg)
CVP (mmHg)
PCWP (mmHg)
CI (L/min/m
2)
Control
Ulinastatin
Control
Ulinastatin
Control
Ulinastatin
Control
Ulinastatin
Control
Ulinastatin
Control
Ulinastatin
75 ± 15
76 ± 18
92 ± 8
103 ± 14
20 ± 7
21 ± 6
7 ± 3
7 ± 3
13 ± 5
14 ± 5
2.9 ± 0.8
3.1 ± 1.0
80 ± 12
83 ± 11
67 ± 9
67 ± 13
17 ± 3
19 ± 4
8 ± 3
9 ± 3
12 ± 2
14 ± 4
2.9 ± 0.6
3.0 ± 0.7
95 ± 19
95 ± 15
79 ± 10
76 ± 13
21 ± 23
15 ± 4
7 ± 3
8 ± 2
12 ± 3
13 ± 3
3.4 ± 0.9
3.1 ± 0.6
89 ± 7
87 ± 11
75 ± 10
76 ± 8
16 ± 3
17 ± 3
7 ± 2
8 ± 2
12 ± 3
13 ± 3
3.2 ± 0.6
3.1 ± 0.6
Values are mean ± SD. T1: 15 min after tracheal intubation, T2: 15 min after sternum closure, T3 and T4: 1 and 24 hours after arrival at the 
intensive care unit, respectively, HR: heart rate, MAP: mean systemic arterial pressure, MPAP: mean pulmonary arterial pressure, CVP: central 
venous pressure, PCWP: pulmonary capillary wedge pressure, CI: cardiac index. 152 www.ekja.org
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patients who underwent aortic valve replacement after CPB. 
The CK-MB values were not significantly different between 
the control and ulinastatin group during the postoperative 
period in this study. A previous study, which was performed in 
adult patients undergoing CABG or valvular surgery with CPB, 
suggested that the administration of 10,000 U/kg ulinastatin 
has no influence on postoperative CK-MB level [20]. However, 
ulinastatin significantly reduces the postoperative increase 
in CK-MB levels at 24 hours after discontinuation of CPB in 
patients who underwent open heart surgery and received 
12,000 U/kg ulinastatin [14]. Additionally, ulinastatin reduces 
the postoperative increase in troponin-I levels in patients who 
underwent off-pump coronary artery bypass graft surgery when 
it was infused initially at a concentration of 6,000 U/kg and 
then at a rate of 1,000 U/kg/hr throughout the surgery [19]. This 
difference in outcomes between our study and these previous 
studies might be due to the degree of systemic inflammatory 
response, type of surgery, and the use of CPB; we found that 
ulinastatin did not effectively exert a myocardial protective 
effect against I/R injury in patients who underwent aortic valve 
replacement using CPB. 
Acute kidney injury is evaluated mainly by measuring post  -
operative levels of creatinine, which is a low sensitivity tech-
nique. Therefore, we assessed whether ulinastatin had a renal 
protective effect by using the renal biomarkers cystatin C and 
NGAL, which predict kidney injury earlier and with more 
sensitivity than creatinine [21]. No significant differences in 
the postoperative levels of these three renal biomarkers were 
observed between the two groups. In previous studies reporting 
that ulinastatin has a renal protective effect after CPB, the renal 
tubular enzyme, N-acetyl-beta-D-glucosaminidase, which is 
collected from urine, was used, and significant differences in 
levels of this enzyme were observed between the control and 
ulinastatin group, but no significant differences were observed 
in creatinine levels between the two groups [12,22]. Ulinastatin 
has also been reported to prevent postoperative aggravation of 
renal function in patients with poor preoperative renal function 
[15]. In contrast, we observed no renal protective effect in this 
study. All patients except three patients in the control group 
and four patients in the ulinastatin group had well-functioning 
kidneys with a glomerular filtration rate > 60 ml/min/1.73 
m
2 preoperatively. Therefore, none of the patients in either 
group experienced acute kidney injury, defined as an absolute 
increase in serum creatinine levels by either 0.3 mg/dl or ≥ 50% 
from baseline [23]. 
Even though the main ulinastatin mechanism of action is to 
suppress the release of PMNE, a critical limitation of this study 
was that we were unable to check whether the administrated 
dose of ulinastatin adequately suppressed PMNE release. 
However, a previous study reported that a smaller dose of 
ulinastatin can inhibit PMNE release [24]. No differences were 
observed between the two groups when we compared the 
white blood cell and neutrophil counts to determine the degree 
of inflammation during the preoperative and postoperative 
periods.
There are several reasons why ulinastatin may not have had 
a myocardial and renal protective effect. First, although we used 
a high dose of ulinastatin compared with other studies, this 
bolus may not have been sufficient to suppress inflammatory 
reactions and activate PMNE, which are persistent during 
CPB. Furthermore, given that the plasma half-life of ulinastatin 
is short at about 40 minutes [25], injection of continuously 
infused high-dose ulinastatin would likely have been more 
effective. Second, the patients who were enrolled had a well-
functioning heart and kidneys preoperatively; therefore, they 
were at low risk for organ injury after CPB, because preoperative 
cardiac and renal function affects postoperative cardiac and 
renal function, respectively. We only included patients who 
had a normal, functioning heart and kidneys to allow us to 
objectively evaluate the effects of ulinastatin. A high dose of 
ulinastatin should be infused continuously in patients with 
poorly functioning kidneys to further investigate the effects of 
ulinastatin during heart surgery with CPB. 
In conclusion, ulinastatin did not effectively reduce CBP-
induced damage to the heart and kidneys of patients who 
underwent an aortic valve replacement. 
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